2024-10-21
Participating in CPHI Worldwid
Release Time: 2020-09-22
News Source: SenovaTech
Author: Operation Dept.
API information:
Product name:Dapagliflozin propanediol monohydrate Cas No.:960404-48-2
Molecular Formula:C24H35ClO9 Molecular Weight:502.9823
Structure:
Key intermediates information:
Product name:5-bromo-2-chloro-4'-ethoxydiphenylmethane
Cas No.:461432-23-5
Molecular Formula:C15H14BrClO Molecular Weight:325.62806
Structure:
Product name:
(2S,3R,4S,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(hydroxyMethyl)-2-Methoxytetrahydro-2H-pyran-3,4,5-triol
Cas No.:714269-57-5
Molecular Formula:C22H27ClO7 Molecular Weight:438.89858
Structure:
Product name:D-Glucitol,1,5-anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)Methyl]phenyl]-, tetraacetate, (1S)-
Cas No.:461432-25-7
Molecular Formula:C29H33ClO10 Molecular Weight:577.01932
Structure:
Product name:Dapagliflozin
Cas No.:461432-26-8
Molecular Formula:C21H25ClO6 Molecular Weight:408.8726
Structure:
.................................................................................................................................................................
Dapagliflozin is a sodium-glucose co-transporter 2 inhibitor. On January 8, 2014, the US Food and Drug Administration (FDA) have approved it for being used in the treatment of type II diabetes.Dapagliflozin works through inhibiting sodium-glucose transporter 2 (SGLT2), a protein in the kidney that reabsorbs glucose into the bloodstream. Meanwhile, FDA requires the producers to conduct post-marketing research on drug-related risks.
Treatment with empagliflozin and dapagliflozin reduces all-cause mortality and improves renal outcomes in patients with heart failure with reduced ejection fraction (HFrEF), suggests a recent study in the journal Lancet.
..................................................................................................................................................................
The global prevalence of diabetes among adults over 18 years of age rose from 4.7% in 1980 to 8.5% in 2014.SENOVE started to study Dapagliflozin API in 2015,The same as Empagliflozin API, it only took two years from small trial to medium trial to commercialization.The capacity of Dapagliflozin API is 500kg/month and The capacity of the key intermediates are 1000~3000kg/month now.
Headquarter Office in ShenZhen, R&D center in HangZhou, GMP factory in JiangSu.
（Please note:All products which might have patent infringment are used for R&D only/ It's Not Senova's responsibility in those markets where there are patent infringement regulated.）
OUR PLANT:
WORKSHOP
R&D ROOM:
WAREHOUSE:
PACKING:
COA:
.................................................................................................................................................................
SENOVA:
Senova means“Step For Innovation", we are a professional company who's supplying APIs(mainly New Generics), Advanced Intermediates and KSM(Key Starting Materials) as well as technical Support/Registration support/Custom synthesis service in pharmaceutical and related field , we focus on serving those manufacturers' New Generics Projects from R&D stage to Commercial Stage from meterials to documents support(DMF/CMC). For those regulated markets, we secure all of our products can be produced under GMP regulation with Full Documentation.
